Michael Staehler

views mine

[Kidney Cancer @KidneyCancer]

Shake the hand of someone who… 🤝 Part ONE!

Connecting across disciplines, experiences, and a shared mission to move kidney cancer research forward.

#IKCSEU26 #KidneyCancer #Oncology #CancerResearch

[OncoAlert @OncoAlert]

DAY Two of OncoAlert 🚨 Coverage of #IKCSEU26
Provider Perceptions of Cure in Renal Cell Cancer Presented by Ms. Dena Battle🇺🇸 of @kcCURE

RCC specialists demonstrate notable hesitancy in using the term “cure,” even in clinical contexts where long-term outcomes may justify it. This reluctance reflects not only clinical uncertainty but also parallels similar reservations among patients. The absence of a standardized definition contributes to inconsistent communication, potentially affecting expectations and decision-making. Establishing clearer, consensus-driven terminology around “cure” in RCC could enhance transparency, improve physician–patient alignment, and support more informed shared decision-making. Addressing this linguistic and conceptual gap may ultimately strengthen trust and facilitate more meaningful discussions about prognosis and treatment goals in renal cell carcinoma care. #KidneyCancer

@KidneyCancer Jean-Christophe Bernhard @univbordeaux @AlbigesL @gustaveroussy @TiansterZhang @Dr_SabyGeorge @ZakhariaYousef @ERPlimackMD @Ric_Campi @DrIacovelli @RebuzziSara @weoncologists @GEVaughan1 @salvolarosa @DrYukselUrun #KidneyCancer @daniyal_jafree @EJonasch @IKCCorg @sophiemerrick1 @BarbaraJereczek @ESTRO_RT @ZakhariaYousef @kuraoncology @Selcuk__Erdem @drulkav @RCCadvocate

[Alexander Kutikov MD @uretericbud]

Still time to register!
Join us this Thursday in Center City for a phenomenal, practice-changing review of everything happening in GU Oncology - and yes, a great meal too!

[KCCure @kcCURE]

Doctors! Tell us YOUR answer! How should the term “cure” be used in #kidneycancer? #ESMO25 Let’s see how many responses we can get! @DrChoueiri @montypal @DrYukselUrun @TiansterZhang @Uromigos @OncoAlert https://t.co/Ckxo46jcg7

[Dena Battle @RCCadvocate]

#ESMO25 starts today! Excited to present #evidencebased data from @kcCURE exploring how metastatic #kidneycancer pts interpret the word “cure.”

[KCCure @kcCURE]

#KidneyCancer Patients want cures—but few believe they’re possible. Learn what patients living with metastatic RCC think about the word “cure." 📍Abstract 2636P | #ESMO25 #KidneyCancer #mRCC @TiansterZhang @spsutkaMD @DrVaishampayan @MichaelStaehler @lisapic @AlbigesL

[Uromigos @Uromigos]

It’s hard to believe Americas 🇺🇸 🇨🇦 3-0 down in the Uromigos Cup 🏆 . Weekly photos from each team from around the world wins points . ❤️ =points. Can the Americas 🇺🇸🇨🇦 catch up ? Here is @walterstadler5 in Chicago. @OncoAlert @montypal @crisuarez08 @DrChoueiri

[Michael Staehler @MichaelStaehler]

@allaf_mo At Macy‘s?

[Toni Choueiri, MD @DrChoueiri]

Final analysis of Checkmate 9ER in @Annals_Oncology : 1L mRCC trial

https://t.co/IVeJwF2r7T

[Ithaar H. Derweesh @Cold_Steel_1970]

I am delighted and honored to join the great team @RushUrology @RushMedical I want to thank my colleagues @UCSDHealth and @UCSD_Urology #Chicago here I come! #KidneyCancer #UrologicOncology @UroOnc @AmerUrol @EECherullo @cjkane10

[Emre Yekedüz @yekeduz_emre]

Phase 2 trial: In oligometastatic clear-cell RCC, serial metastasis-directed therapy (no systemic Tx) achieved median 34 mo systemic therapy-free survival & 17.7 mo PFS with low grade 3–4 toxicity. A promising option for select pts.

🔎To finish discussion need to 3 arms phase-3 trial:
👉MDT only vs. Systemic Tx only vs. MDT+Systemic Tx

@OncoAlert @TheLancet #cancer #Oncology #MedX

https://t.co/V7p5if1kBw

[Michael Staehler @MichaelStaehler]

@uretericbud @cancerdrlane Influenced so many patients and colleagues - much more than he ever knew. Heaven will welcome him but we will miss this true giant in the field. Rest peacefully

[Michael Staehler @MichaelStaehler]

@TiansterZhang @andyzwang @utswcancer @UTSW_RadOnc @UTSWMedCenter So well deserved! Congratulations 🎈🍾🎉

[Neeraj Agarwal, MD, FASCO @neerajaiims]

Just came online in @TheLancet 👉Our two papers on improved OS with Enzalutamide + Talazoparib in mCRPC #ProstateCancer in all-comer & HRRm patients (Median OS and HRs👇). Weblinks to the papers👉 https://t.co/AMqlUvlkNG and https://t.co/W8gO8lWxQo @PCFnews @urotoday @OncoAlert

[Michael Staehler @MichaelStaehler]

@LauraBukavinaMD @CleClinicUro @cjweight @drjkaouk @CanDAydogdu You nailed it!

[PeerView @PeerView]

Join Dr. Sumanta Kumar Pal (@montypal) & colleagues on Saturday, May 31, at 6:30 PM CDT/7:30 PM EDT during #ASCO25 for a #RenalCellCarcinoma #MedEd event. Produced with @KCCure. https://t.co/lJkRO9K17V #KidneyCancer #Oncology

[KCCure @kcCURE]

📣 Live at #ASCO25: Learn from real-world #RCC cases with @montypal, Dr. McDermott & @TiansterZhang
 ✅ IO-based regimens
 ✅ Sequencing therapies
 ✅ Shared decision-making
 🗓️ May 31 | 7:00 PM CDT
 🔗 https://t.co/PNSrNPyw2J

[Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky) @TiansterZhang]

Just a week away!
Please join us in Chicago at this Peerview event, 7pm central on Sat 5/31!
Register here:
https://t.co/MeSV8wffTi

[Michael Staehler @MichaelStaehler]

@LauraBukavinaMD @gabrielamdd @LMU_Muenchen @CleClinicUro @cjweight @LauraBukavinaMD you are too kind. I am sure both will thrive under your mentorship and learn a bunch from you and the team @CleClinicUro ! @CanDAydogdu

[Michael Staehler @MichaelStaehler]

@DrIacovelli @salvolarosa @lisapic @tompowles1 @GEVaughan1 @AlbigesL @TiansterZhang @RCCadvocate @KidneyCancer @danieleamparore It’s the #kidneycancer family coming together 😉